High-dose cis-platinum in combination with adriamycin in the treatment of ovarian carcinoma.
Although promising potential of high dose cis-platinum in the treatment of ovarian carcinoma has been reported (6,7), a combination of adriamycin (60 mg/m2) and high dose cis-platinum (100 mg/m2) in 9 patients with advanced or recurrent ovarian carcinoma revealed no improved response compared to 13 patients receiving adriamycin (60 mg/m2) and cis-platinum (60 mg/m2). In addition to increased marrow toxicity, there is suggestion of synergism of cis-platinum to adriamycin cardiotoxicity. The efficacy of other agent/agents in combination with high dose cis-platinum should further be investigated.